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Background: Nintedanib is a potent, oral angiokinase inhibitor that targets VEGF, PDGF and FGF signalling, as well as
RET and Flt3. The maximum tolerated dose of nintedanib was evaluated in a phase I study of treatment-refractory
patients with advanced solid tumours. In this preplanned subanalysis, the effect of nintedanib on the tumour
vasculature, along with efficacy and safety, was assessed in 30 patients with colorectal cancer (CRC).
Methods: Patients with advanced CRC who had failed conventional treatment, or for whom no therapy of proven
efficacy existed, were treated with nintedanib ranging from 50–450 mg once-daily (n = 14) or 150–250 mg twice-daily
(n = 16) for 28 days. After a 1-week rest, further courses were permitted in the absence of progression or undue toxicity.
The primary objective was the effect on the tumour vasculature using dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI) and expressed as the initial area under the DCE-MRI contrast agent concentration–time curve
after 60 seconds (iAUC60) or the volume transfer constant between blood plasma and extravascular extracellular
space (Ktrans).
Results: Patients received a median of 4.0 courses (range: 1–13). Among 21 evaluable patients, 14 (67%) had
a ≥40% reduction from baseline in Ktrans and 13 (62%) had a ≥40% decrease from baseline in iAUC60, representing
clinically relevant effects on tumour blood flow and permeability, respectively. A ≥40% reduction from baseline in
Ktrans was positively associated with non-progressive tumour status (Fisher’s exact: p = 0.0032). One patient
achieved a partial response at 250 mg twice-daily and 24 (80%) achieved stable disease lasting ≥8 weeks. Time to
tumour progression (TTP) at 4 months was 26% and median TTP was 72.5 days (95% confidence interval: 65–114).
Common drug-related adverse events (AEs) included nausea (67%), vomiting (53%) and diarrhoea (40%); three
patients experienced drug-related AEs ≥ grade 3. Four patients treated with nintedanib once-daily had an alanine
aminotransferase and/or aspartate aminotransferase increase ≥ grade 3. No increases > grade 2 were seen in the
twice-daily group.
Conclusions: Nintedanib modulates tumour blood flow and permeability in patients with advanced, refractory
CRC, while achieving antitumour activity and maintaining an acceptable safety profile.
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Angiogenic growth factors, including vascular endo-
thelial growth factor (VEGF), platelet-derived growth
factor (PDGF) and fibroblast growth factor (FGF), and
their receptors play an essential role in tumour angio-
genesis [1-3]. As VEGF, acting via its endothelial recep-
tors (VEGFR-1–3), is the most important regulator of
physiological and pathological angiogenesis [1], most
research into antiangiogenic therapies has focused on
this signalling pathway. However, not all neoplasms
respond to anti-VEGF/VEGFR agents and most, if not
all, tumours that initially respond eventually develop
resistance to such therapies [3]. This ‘tumour escape’,
which is often observed under sustained VEGF/VEGFR
inhibition, is likely to be due, at least in part, to compensa-
tory angiogenic signalling, including that mediated by the
PDGF/PDGFR and FGF/FGFR pathways [3-12]. There is
also growing evidence to indicate a role for FGF and
PDGF signalling in reducing the clinical efficacy of VEGF/
VEGFR-targeted agents [13-15]. A role for agents with
broader molecular specificity than VEGF/VEGFR alone is
therefore suggested.
Lack of response and therapeutic resistance to antian-
giogenic therapies is a particular problem in advanced
colorectal cancer (CRC) [16,17], as exemplified by the
growing number of unsuccessful phase III trials in which
tyrosine kinase inhibitor/chemotherapy combinations (e.g.,
cediranib plus FOLFOX [5-fluorouracil, leucovorin and
oxaliplatin] or CAPOX [capecitabine and oxaliplatin],
vatalanib plus FOLFOX, sunitinib plus FOLFIRI [folinic
acid, fluorouracil and irinotecan]) have failed to im-
prove overall survival (OS) versus chemotherapy alone
or chemotherapy combined with the anti-VEGF antibody
bevacizumab (recommended as initial treatment for
metastatic CRC in combination with fluoropyrimidine-
based chemotherapy [18,19]) in first- or second-line
use [18,20-23]. In contrast to these disappointing results,
a recent phase III trial has demonstrated improved OS
with the oral multikinase inhibitor regorafenib plus best
supportive care (BSC) versus placebo plus BSC in patients
with metastatic CRC who had progressed after failing all
approved standard therapies [24]. These findings highlight
the potential of angiogenesis inhibitors as salvage therapy
in metastatic CRC.
Based on its broad mechanism of action (including
inhibition of VEGFR 1–3, FGFR 1–3, PDGFR-α/β, RET
and Flt3 [25]) and consequent potential to overcome com-
pensatory angiogenic signalling, we explored the safety,
pharmacokinetics and pharmacodynamics of the novel
multi-angiokinase inhibitor nintedanib (BIBF 1120) in a
phase I trial involving treatment-refractory patients with a
range of advanced solid tumours [26]. As a preplanned ex-
ploratory subanalysis of this phase I study, we assessed the
effect of nintedanib on the tumour vasculature in patientswith heavily pretreated, advanced CRC using dynamic
contrast-enhanced magnetic resonance imaging (DCE-
MRI), a non-invasive imaging technique used to monitor
changes in tumour haemodynamics [27]. The clinical effi-
cacy and safety of the drug were also evaluated, as well as
correlations between DCE-MRI parameters and clinical




Patients included in the phase I study were adults with
advanced, non-resectable and/or metastatic, measurable
solid tumours who had failed conventional treatment or
for whom no therapy of proven efficacy existed; only
patients with CRC were included in this subanalysis. To
be enrolled, patients had to have an Eastern Cooperative
Oncology Group performance status (ECOG PS) of 0 to
2, and a life expectancy of at least 3 months, and must
have made a complete recovery from all prior treatment-
related toxicities.
The main exclusion criteria included surgery, radiother-
apy or investigational anticancer therapy (excluding ninte-
danib) during the previous 4 weeks; active ulcers or
infectious disease; injuries with incomplete wound healing;
pregnancy or breastfeeding; brain metastases requiring
therapy; absolute neutrophil count <1,500/mm3; platelet
count <100,000/mm3; bilirubin >1.5 mg/dL; aspartate
amino transferase (AST) and/or alanine amino transfer-
ase (ALT) >3 × the upper limit of normal (or >5 × the
upper limit of normal if related to liver metastases);
serum creatinine >1.5 mg/dL; uncontrolled severe hyper-
tension; and gastrointestinal disorders anticipated to inter-
fere with the resorption of study medication.
Study design
The phase I trial was an open-label, single and multiple
dose study, with accelerated, toxicity-guided dose escal-
ation [26]. The first treatment cycle comprised a single
oral dose of nintedanib (Boehringer Ingelheim Pharma
GmbH & Co. KG; administered as 50 and/or 200 mg cap-
sules after food) on day 1, followed by a 1-day washout
and 28 days of continuous once- or twice-daily oral ad-
ministration of fixed-dose nintedanib. After a 1-week rest
period, further cycles were permitted in the absence of
major tumour progression (defined as an increase of ≥30%
in the sum of the longest diameters of target lesions) or
dose-limiting toxicity (DLT; defined as any drug-related
toxicity ≥Common Toxicity Criteria [CTC] grade 3, with
the exception of alopecia or untreated vomiting).
The full dose-escalation protocol has been described
previously [26]. Among patients with CRC, the following
dose levels were evaluated: once-daily (morning) doses
of 50, 100, 200, 250, 300 and 450 mg; and twice-daily
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200 and 2 × 250 mg. Dose tiers were evaluated in separ-
ate patient cohorts, and intrapatient dose escalation was
not permitted. Antiemetic prophylaxis was not allowed.
The primary objective of this preplanned subanalysis
was to assess the effect of continuous daily dosing with
nintedanib on the tumour vasculature in patients with
CRC using DCE-MRI. Additional objectives included
evaluation of tumour response, time to first tumour pro-
gression (TTP) and safety/tolerability.
The protocol was approved by the local medical eth-
ics committee (Ethik-Kommission der Albert-Ludwigs-
Universität Freiburg), and the trial was conducted in
accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines. All patients provided written
informed consent prior to engaging in study procedures.Assessments
Dynamic contrast-enhanced magnetic resonance imaging
Full details of the DCE-MRI protocol that was used
have been published previously [28,29]. In brief, coronal
slice images through one or more measurable, clearly
defined, non-necrotic target lesions were obtained at
baseline (screening), on day 2 for once-daily dosing or day
3 for twice-daily dosing, and on day 29/30 of the first
treatment cycle immediately prior to and following intra-
venous administration of contrast agent (low-molecular
weight gadolinium-DTPA) via a standard power injector.
Additional images were obtained on day 28 of each re-
peated cycle for all patients remaining in the trial.
All imaging data were acquired using a clinical 1.5-Tesla
whole-body magnetic resonance system (Sonata, Siemens,
Germany) applying the T1-weighted inversion recovery
TrueFISP pulse sequence, an approach that offers high
temporal resolution and accuracy at least as good as the
widely used 3D-Flash protocol [29,30]. The data obtained
from the scans were used to determine the change in con-
trast agent concentration in tumour tissue over time.
For this analysis, the two endpoints of interest were (1)
the initial area under the contrast agent concentration–
time curve for the initial 60 seconds after onset of contrast
agent uptake (iAUC60); and (2) the transfer constant for
the transfer of contrast agent from inside tumour blood
vessels to the extravascular-extracellular space (Ktrans).
Both parameters, which are influenced by blood flow
and vascular permeability properties of the tumour,
were calculated from the imaging data using standard
methods [31,32].Tumour assessment
Target tumour lesions were assessed by computed
tomography or MRI according to Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.0 [33].Tumour evaluations were undertaken at baseline and
at the end of each treatment cycle.
Safety and tolerability
The safety and tolerability of nintedanib were assessed
by adverse event (AE) reporting, physical examination,
vital signs, 12-lead resting electrocardiogram and labora-
tory safety parameters. AEs were recorded at each sched-
uled visit and graded according to CTC version 2.0. Safety
laboratory parameters (haematology, coagulation parame-
ters, clinical chemistry, tumour markers and urinalysis)
were assessed at regular intervals throughout the study.
Statistical analyses
Analyses were restricted to CRC patients who had re-
ceived at least one dose of nintedanib and for whom
data at and/or after baseline were available. For the
DCE-MRI analysis, the proportion of evaluable patients
(i.e., those with measurable, non-necrotic target tumour
lesions) with a ≥40% reduction from baseline in tumour
Ktrans or iAUC60 was determined, as this represents the
threshold for a clinically relevant antivascular response
[34]. Logistic regression models were fitted with DCE-
MRI response parameters (<40% vs. ≥40% reduction from
baseline in Ktrans or iAUC60) as explanatory variables and
clinical outcome (complete or partial response, or stable
disease vs. disease progression) as the dependent variable.
Two-sided Fisher’s exact tests were then used to investi-
gate contingencies (i.e., the generic correlation) between
DCE-MRI responses and clinical outcome. p-values
of <0.05 were reported as nominally significant.
Tumour responses and safety variables were analysed
using descriptive statistics, and TTP (defined as the time
elapsed from first administration of study medication to
tumour progression) was estimated using Kaplan-Meier
methodology. A log-rank test was used to compare the
Kaplan-Meier curves for TTP between the two dosing
schedules (once- vs. twice-daily) of nintedanib.
Results
Patients
A total of 30 patients with advanced, non-resectable
and/or metastatic CRC were treated with increasing
doses of nintedanib once- (n = 14) or twice- (n = 16)
daily at a single centre in Germany between November
2002 and November 2004. The demographics and base-
line characteristics of patients within this highly treatment-
refractory CRC subgroup are shown in Table 1. Although
most baseline parameters were well balanced, there
were some quantitative differences between the two
dosing groups (once- vs. twice-daily) in terms of sex,
time since diagnosis, clinical stage at diagnosis and lung
metastases. All patients had metastatic CRC (≥1 meta-
static site) and had received 1–5 lines of chemotherapy








Median age, years (range) 58.0 (41–74) 59.5 (34–74)
Sex, n (%)
Male 9 (64) 15 (94)
Female 5 (36) 1 (6)
ECOG performance status, n (%)
0 2 (14) 5 (31)
1 10 (71) 10 (63)
2 1 (7) 1 (6)
Unknown 1 (7) 0
Median time since diagnosis, days
(range)
733 (325–2,214) 1,006 (229–2,968)
Prior treatment for CRC, n (%)
Chemotherapy 14 (100) 16 (100)
Radiotherapy 4 (29) 5 (31)
Surgery 14 (100) 16 (100)
Immunotherapy 1a (7) 0
Hormone therapy 1 (7) 1 (6)
Clinical stage at diagnosis, n (%)
Stage I 0 2 (13)
Stage II 1 (7) 1 (6)
Stage III 1 (7) 7 (44)
Stage IV 12 (86) 6 (38)
Location of metastatic sites,b n (%)
Lung 5 (38) 9 (56)
Liver 10 (71) 11 (69)
Lymph nodes 6 (43) 7 (44)
Bone 1 (7) 0
Median number of metastatic
sites, n (range)
2 (1–4) 2 (1–5)
Percentages may not add up to 100% due to rounding. aPatient received
panorex; bNot all metastatic sites are listed. Abbreviations: CRC = colorectal
cancer, ECOG = Eastern Cooperative Oncology Group.
Table 2 Patient exposure to nintedanib
Dose (once-daily) Patients (n) Dose (twice-daily) Patients (n)
50 mg 1 150 mg × 2 4
100 mg 1 150 mg + 200 mg 4
200 mg 4 200 mg × 2 1
250 mg 4 250 mg × 2 7
300 mg 2 – –
450 mg 2 – –
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bevacizumab or cetuximab prior to study inclusion; one
patient had received sorafenib which at the time of the
study was considered an RAF kinase inhibitor rather
than a multikinase angiogenesis inhibitor. One patient
had previously received adjuvant chemo-radiotherapy
and was included in the study after rejecting all stand-
ard treatments. The patient was subject to two dose re-
ductions and subsequently excluded from the study due
to DLT.
Patients on the once-daily schedule of nintedanib re-
ceived doses of between 50 and 450 mg once-daily, while
those on the twice-daily schedule received doses ofbetween 150 (total dose 300 mg/day) and 250 (total dose
500 mg/day) mg twice-daily (Table 2). Overall, patients
were treated for a median of 4.0 cycles (range: 1–13 cy-
cles) with 15 of the 30 patients (50%) receiving >2 cycles.
Of the 30 patients who were enrolled, 15 (50%) contin-
ued study treatment until disease progression.
Dynamic contrast-enhanced magnetic resonance imaging
Twenty-one patients with CRC were evaluable for DCE-
MRI. In total, 14 of the 21 patients with evaluable DCE-
MRI data (67%) had a ≥40% reduction from baseline in
tumour Ktrans, representing a clinically relevant antivas-
cular effect [34]. Similarly, 13 of the 21 patients (62%)
had a ≥40% decrease from baseline in tumour iAUC60.
In the correlative analyses, a ≥40% reduction from
baseline in Ktrans was shown to be positively associated
with non-progressive tumour status (complete or partial
response, or stable disease; Fisher’s exact test: p = 0.0032).
Figure 1 shows parameter maps of Ktrans, taken pretreat-
ment, and on days 2 and 28, from a patient with liver me-
tastases who received nintedanib 250 mg once-daily. As
shown in Figure 2a, Ktrans and iAUC60 decreased relative
to baseline over time in this patient who had stable disease
according to RECIST. A strong reduction in contrast
agent uptake was observed relative to baseline in the
target tumour lesion from this patient on both day 2
and day 28 (Figure 2b).
Efficacy
One patient (3%) with CRC and liver metastasis who
was treated with nintedanib 250 mg twice-daily achieved
a partial response, while 24 patients (80%) treated with
either schedule at various dose levels had a best response
of stable disease lasting ≥8 weeks.
Based on Kaplan-Meier estimates (including data from
patients who rolled over to an extension study, but ex-
cluding data from one patient in which TTP was cen-
sored, and censoring time was not available), median
TTP was 71 days (95% confidence interval [CI]: 48–134
days) among patients who received once-daily ninteda-
nib and 106 days (95% CI: 37–115 days) among patients
who received the twice-daily schedule (Figure 3). The
difference between the two dosing schedules was not








(c) Day 28(b) Day 2(a) Pretreatment
Figure 1 Ktrans maps from a patient with liver metastases treated with nintedanib 250 mg once-daily (#18). Maps were registered to
original TrueFISP images taken (a) pretreatment, (b) on day 2 and (c) on day 28. Abbreviation: Ktrans = volume transfer constant between blood
plasma and extravascular extracellular space.
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luable patients with CRC, the 4-month TTP rate was
26% (95% CI: 17–43%) and median TTP was 72.5 days
(95% CI: 65–114 days).
Safety and tolerability
The most frequent drug-related AEs reported across all
treatment cycles and dose levels/schedules were nausea,
vomiting and diarrhoea (Table 3). The majority of drug-
related AEs were CTC grade 1 or 2 in intensity, including
all gastrointestinal AEs (Table 3), and mostly occurred
during the first treatment cycle independently of the dos-
ing schedule (data not shown). Drug-related AEs ≥CTC
grade 3 were only seen in three patients, all of whom had
received the twice-daily schedule of nintedanib. Two
patients experienced CTC grade 1 drug-related hyper-






























Figure 2 DCE-MRI parameters in a patient with liver metastases treat
and iAUC60 from baseline over time; and (b) concentration–time curves for
day 2 and day 28. Both figures illustrate a strong reduction of contrast age
assessments. Abbreviations: DCE-MRI = dynamic contrast-enhanced magne
plasma and extravascular extracellular space, iAUC60 = initial area under theFour of the 14 patients treated with once-daily ninteda-
nib experienced an increase in ALT and/or AST ≥CTC
grade 3. In contrast, there were no ALT/AST increases >
CTC grade 2 in the 16 patients receiving twice-daily ninte-
danib. Most increases in hepatic enzymes reported during
twice-daily dosing were seen after the first treatment cycle.
No treatment-related elevations in bilirubin or alkaline
phosphatase were observed in either dosing group.
Discussion
While the injectable anti-VEGF monoclonal antibody bev-
acizumab is a well-established first-/second-line treatment
option for advanced CRC [18,19], trials of oral, small mol-
ecule antiangiogenic agents have been largely unsuccessful
in this setting. To date, the only oral antiangiogenic ther-
apy to have succeeded in a phase III trial in advanced CRC
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Figure 3 Kaplan-Meier plot showing time to first tumour progression by nintedanib dosing schedule. The shaded areas represent 95%
confidence intervals. Abbreviations: BID = twice-daily, QD = once-daily.
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[24,35,36]. In this phase III trial, regorafenib plus
BSC significantly increased median OS by 1.4 months
compared with placebo plus BSC (6.4 vs. 5.0 months,
respectively; HR: 0.77 [95% CI: 0.64–0.94]; p = 0.0052) in
patients who had progressed after all standard therapies.
These positive results indicate a role for small moleculeTable 3 Summary of nintedanib-related toxicities
Patients with drug-related AEs, n (%) 1
Total 18 (60)










General disorders 5 (17)
Fatigue 5 (17)
Abbreviations: AE adverse event, ALT alanine aminotransferase, AST aspartate amino
transpeptidase.antiangiogenic therapies in the treatment of advanced
CRC, at least in the salvage setting.
In our prospective subanalysis of a phase I trial [26],
DCE-MRI was used to investigate the effects of the oral
angiokinase inhibitor nintedanib (administered once- or
twice-daily) on tumour blood perfusion and vascular per-
meability in 30 patients with heavily pretreated, advanced,CTC grade, n (%)
2 3 4 Total
6 (20) 2 (7) 1 (3) 27 (90)
7 (23) 0 0 23 (77)
4 (13) 0 0 20 (67)
2 (7) 0 0 16 (53)
5 (17) 0 0 12 (40)
1 (3) 2 (7) 1 (3) 6 (20)
1 (3) 0 1 (3) 2 (7)
1 (3) 0 0 1 (3)
1 (3) 1 (3) 0 2 (7)
1 (3) 0 0 1 (3)
0 2 (7) 0 2 (7)
0 0 0 5 (17)
0 0 0 5 (17)
transferase, CTC Common Toxicity Criteria, GGT gamma-glutamyl
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teristics akin to those seen in patients enrolled in the
regorafenib phase III trial [24]. DCE-MRI utilises a
low-molecular weight paramagnetic contrast agent (in
this case gadolinium-DTPA) that diffuses readily from
the tumour blood supply to the extravascular extracel-
lular space. On acquisition of rapid images, the time
course of the signal intensity change induced by the
contrast agent, which directly reflects its intra- and
extravascular concentration in the tumour region of
interest, may be followed.
The results of our analysis showed that, like many
other angiogenesis inhibitors [37-45], nintedanib can
exert clinically meaningful antiangiogenic effects on the
tumour vasculature (in >60% of evaluable patients), as
defined by ≥40% reductions from baseline in iAUC60
and Ktrans [34]. The strong antivascular effect seen with
nintedanib may result from its potential to simultaneously
inhibit multiple angiogenic and mitogenic signalling path-
ways (mediated by VEGFR, PDGFR, FGFR, RET and Flt3
[25]), which may enable the drug to block compensatory
angiogenic pathways that can be activated when anti-
VEGF agents are used in isolation [3-12].
Despite some inter-patient variability in DCE-MRI
parameters, a ≥40% reduction from baseline in Ktrans
was shown to be positively associated with non-
progressive tumour status (p = 0.0032). This finding
suggests that DCE-MRI Ktrans response may be a po-
tential marker of disease control during nintedanib
treatment. Importantly, the results mirror those in the
overall phase I population and support other data sug-
gesting DCE-MRI as a potentially useful surrogate marker
for defining the pharmacological response to angiogenesis
inhibitors in CRC [26,34,46,47].
In the RECIST analysis of tumour response, one patient
achieved a partial response and a further 24 achieved
stable disease lasting for ≥8 weeks, resulting in a disease
control rate of 83%, 4-month TTP rate of 26% and median
TTP of 72.5 days. These efficacy data are very similar to
those obtained with regorafenib in the aforementioned
phase III study of 760 patients with metastatic CRC who
had failed all standard therapies [24]. In the phase III trial,
4-month progression-free survival (PFS) was 20% in the
regorafenib plus BSC arm and 4% in the placebo plus BSC
arm. The data are also comparable to those seen in an
earlier phase I dose-escalation, monotherapy study of
regorafenib in 53 patients with treatment-refractory ad-
vanced solid tumours, where a disease control rate of
66% was reported [48]. Among 38 patients with heavily
pretreated advanced CRC (median 4 prior lines of ther-
apy), who were enrolled in an expansion cohort to this
regorafenib phase I trial, the disease control rate was
74% and median PFS was 107 days [36]. Although fur-
ther studies are clearly needed, the similarity of theTTP/PFS data and patient populations between the re-
gorafenib trials and the present subanalysis implies that
nintedanib may be potentially active in the salvage
setting.
The activity of nintedanib in CRC is further supported
by recent data demonstrating similar efficacy and im-
proved tolerability of nintedanib plus modified FOLFOX6
versus bevacizumab plus mFOLFOX6 in a randomised
phase II study of 126 patients with previously untreated
metastatic CRC [21]. In the phase II trial, 9-month PFS
was shown to be 63% (95% CI: 50–75%) in the nintedanib
plus mFOLFOX6 arm versus 69% (95% CI: 53–86%) in
the bevacizumab plus mFOLFOX6 arm, while median
PFS was 10.6 months (95% CI: 9.4–12.3 for nintedanib/
mFOLFOX6 and 9.1–not reached for bevacizumab/
mFOLFOX6) in both arms. The objective response rate
was 61% and 54%, respectively. In terms of safety, ninteda-
nib plus mFOLFOX6 was associated with lower incidences
of serious AEs (34% vs. 54%) and serious gastrointestinal
AEs (12% vs. 29%) than bevacizumab plus mFOLFOX6,
indicating improved tolerability of the nintedanib-
containing regimen [21].
Reassuringly, the safety profile of nintedanib observed
in the present study was entirely consistent with that
seen in other monotherapy studies conducted in patients
with a range of solid tumours, including CRC [26,49-52].
Nintedanib doses of up to 500 mg/day were generally
well tolerated with no reports of new or unexpected tox-
icities. The most common drug-related toxicities were
mild or moderate gastrointestinal AEs (nausea, vomiting
and diarrhoea) and mild or moderate, reversible hepatic
enzyme elevations. Most gastrointestinal AEs occurred
during the first treatment cycle and responded well to
medical intervention. Furthermore, all hepatic enzyme in-
creases responded quickly (within 2 weeks) to treatment
interruption/discontinuation or dose reduction. Unlike
other angiogenesis inhibitors, such as regorafenib, pazopa-
nib, sorafenib or sunitinib [24,36,48,53-56], nintedanib
was not associated with skin toxicity, and reports of hyper-
tension (n = 2, both CTC grade 1) were uncommon; these
findings suggest a favourable comparative safety profile for
nintedanib.
In terms of limitations, this subanalysis is clearly con-
strained by the non-randomised design of the phase I
study and limited sample size. Nevertheless, analyses
such as these are useful for hypothesis generation, and
some of the interesting findings reported here warrant
further investigation.
Conclusions
DCE-MRI assessments of iAUC60 and K
trans responses
provide evidence that the multi-angiokinase inhibitor
nintedanib can modulate tumour blood flow and perme-
ability in patients with advanced, refractory CRC, while
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RECIST response of stable disease or better was also ob-
served in >80% of this population of heavily pretreated
patients; encouraging results that support further clinical
investigation of nintedanib in this salvage setting.
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